Published in PLoS One on May 07, 2015
Critical Role of Tumor Microenvironment in Shaping NK Cell Functions: Implication of Hypoxic Stress. Front Immunol (2015) 0.82
Exploiting the Immunogenic Potential of Cancer Cells for Improved Dendritic Cell Vaccines. Front Immunol (2016) 0.78
Transpresentation of interleukin-15 by IL-15/IL-15Rα mRNA-engineered human dendritic cells boosts antitumoral natural killer cell activity. Oncotarget (2015) 0.76
Bortezomib augments lymphocyte stimulatory cytokine signaling in the tumor microenvironment to sustain CD8+T cell antitumor function. Oncotarget (2016) 0.75
Mouse IP-10 Gene Delivered by Folate-modified Chitosan Nanoparticles and Dendritic/tumor Cells Fusion Vaccine Effectively Inhibit the Growth of Hepatocellular Carcinoma in Mice. Theranostics (2017) 0.75
Desirable cytolytic immune effector cell recruitment by interleukin-15 dendritic cells. Oncotarget (2017) 0.75
Independent control of natural killer cell responsiveness and homeostasis at steady-state by CD11c+ dendritic cells. Sci Rep (2016) 0.75
Combination strategies to enhance the potency of monocyte-derived dendritic cell-based cancer vaccines. Immunotherapy (2016) 0.75
CD56 in the Immune System: More Than a Marker for Cytotoxicity? Front Immunol (2017) 0.75
The biology of human natural killer-cell subsets. Trends Immunol (2001) 10.10
Dendritic cells prime natural killer cells by trans-presenting interleukin 15. Immunity (2007) 5.50
Human natural killer cells: a unique innate immunoregulatory role for the CD56(bright) subset. Blood (2001) 5.23
Regulation of human NK-cell cytokine and chemokine production by target cell recognition. Blood (2009) 3.46
Natural-killer cells and dendritic cells: "l'union fait la force". Blood (2005) 3.10
Distinct roles of IL-12 and IL-15 in human natural killer cell activation by dendritic cells from secondary lymphoid organs. Proc Natl Acad Sci U S A (2004) 2.66
The abundant NK cells in human secondary lymphoid tissues require activation to express killer cell Ig-like receptors and become cytolytic. J Immunol (2004) 2.64
IL-15Ralpha chaperones IL-15 to stable dendritic cell membrane complexes that activate NK cells via trans presentation. J Exp Med (2008) 2.33
Dendritic-cell-based therapeutic cancer vaccines. Immunity (2013) 2.29
Response of human natural killer (NK) cells to NK cell stimulatory factor (NKSF): cytolytic activity and proliferation of NK cells are differentially regulated by NKSF. J Exp Med (1992) 2.26
NKG2D ligands in tumor immunity. Oncogene (2008) 2.26
Immunotherapy of cancer in 2012. CA Cancer J Clin (2012) 2.12
Interleukin 15 skews monocyte differentiation into dendritic cells with features of Langerhans cells. J Exp Med (2001) 1.85
Cutting edge: murine dendritic cells require IL-15R alpha to prime NK cells. J Immunol (2004) 1.85
Induction of complete and molecular remissions in acute myeloid leukemia by Wilms' tumor 1 antigen-targeted dendritic cell vaccination. Proc Natl Acad Sci U S A (2010) 1.84
Revisiting human natural killer cell subset function revealed cytolytic CD56(dim)CD16+ NK cells as rapid producers of abundant IFN-gamma on activation. Proc Natl Acad Sci U S A (2010) 1.74
Human natural killer cell adhesion molecules. Differential expression after activation and participation in cytolysis. J Immunol (1990) 1.74
Human monocytes constitutively express membrane-bound, biologically active, and interferon-gamma-upregulated interleukin-15. Blood (1999) 1.71
Clinical use of dendritic cells for cancer therapy. Lancet Oncol (2014) 1.63
Role of trans-cellular IL-15 presentation in the activation of NK cell-mediated killing, which leads to enhanced tumor immunosurveillance. Blood (2004) 1.62
The small subset of CD56brightCD16- natural killer cells is selectively responsible for both cell proliferation and interferon-gamma production upon interaction with dendritic cells. Eur J Immunol (2004) 1.50
IL-15-induced human DC efficiently prime melanoma-specific naive CD8+ T cells to differentiate into CTL. Eur J Immunol (2007) 1.45
DC-NK cell cross talk as a novel CD4+ T-cell-independent pathway for antitumor CTL induction. Blood (2005) 1.39
Functional significance of the activation-associated receptors CD25 and CD69 on human NK-cells and NK-like T-cells. Immunobiology (2003) 1.30
Mature myeloid dendritic cell subsets have distinct roles for activation and viability of circulating human natural killer cells. Blood (2004) 1.29
Functional heterogeneity of Leu 19"bright"+ and Leu 19"dim"+ lymphokine-activated killer cells. J Immunol (1989) 1.15
Natural killer cell immune escape in acute myeloid leukemia. Leukemia (2012) 1.10
Human NK cells: from surface receptors to the therapy of leukemias and solid tumors. Front Immunol (2014) 1.09
Dendritic cell-induced activation of adaptive and innate antitumor immunity. J Immunol (2003) 1.08
Short-term cultured, interleukin-15 differentiated dendritic cells have potent immunostimulatory properties. J Transl Med (2009) 1.05
Mature cytotoxic CD56(bright)/CD16(+) natural killer cells can infiltrate lymph nodes adjacent to metastatic melanoma. Cancer Res (2013) 1.05
CD56(bright)perforin(low) noncytotoxic human NK cells are abundant in both healthy and neoplastic solid tissues and recirculate to secondary lymphoid organs via afferent lymph. J Immunol (2014) 1.04
Interleukin-15-induced CD56(+) myeloid dendritic cells combine potent tumor antigen presentation with direct tumoricidal potential. PLoS One (2012) 1.04
Dendritic cell derived cytokines in human natural killer cell differentiation and activation. Front Immunol (2013) 1.03
Monocyte surface-bound IL-15 can function as an activating receptor and participate in reverse signaling. J Immunol (2004) 1.02
Recombinant vesicular stomatitis virus transduction of dendritic cells enhances their ability to prime innate and adaptive antitumor immunity. Mol Ther (2009) 1.00
NK cells are required for dendritic cell-based immunotherapy at the time of tumor challenge. J Immunol (2014) 0.99
Dendritic cells (DC) promote natural killer (NK) cell functions: dynamics of the human DC/NK cell cross talk. Eur Cytokine Netw (2002) 0.99
Activating signals dominate inhibitory signals in CD137L/IL-15 activated natural killer cells. J Immunother (2011) 0.98
NK cells: key to success of DC-based cancer vaccines? Oncologist (2012) 0.98
Monocytes differentiated with IL-15 support Th17 and Th1 responses to wheat gliadin: implications for celiac disease. Clin Immunol (2010) 0.96
Monocytes differentiated with GM-CSF and IL-15 initiate Th17 and Th1 responses that are contact-dependent and mediated by IL-15. J Leukoc Biol (2011) 0.96
Enhanced antitumor immunity elicited by dendritic cell vaccines is a result of their ability to engage both CTL and IFN gamma-producing NK cells. Mol Ther (2007) 0.95
Cross-Talks between Natural Killer Cells and Distinct Subsets of Dendritic Cells. Front Immunol (2014) 0.94
CD56 marks human dendritic cell subsets with cytotoxic potential. Oncoimmunology (2013) 0.93
NK cell activation by dendritic cell vaccine: a mechanism of action for clinical activity. Cancer Immunol Immunother (2005) 0.91
IL-15 cis presentation is required for optimal NK cell activation in lipopolysaccharide-mediated inflammatory conditions. Cell Rep (2013) 0.90
Inflammation-restraining effects of prostaglandin E2 on natural killer-dendritic cell (NK-DC) interaction are imprinted during DC maturation. Blood (2011) 0.89
Tumoricidal activity of human dendritic cells. Trends Immunol (2013) 0.87
Poly(I:C) enhances the susceptibility of leukemic cells to NK cell cytotoxicity and phagocytosis by DC. PLoS One (2011) 0.87
DC therapy induces long-term NK reactivity to tumors via host DC. Eur J Immunol (2009) 0.85
NK cells provide helper signal for CD8+ T cells by inducing the expression of membrane-bound IL-15 on DCs. Int Immunol (2009) 0.85
Fast dendritic cells stimulated with alternative maturation mixtures induce polyfunctional and long-lasting activation of innate and adaptive effector cells with tumor-killing capabilities. J Immunol (2013) 0.84
Klebsiella pneumoniae-triggered DC recruit human NK cells in a CCR5-dependent manner leading to increased CCL19-responsiveness and activation of NK cells. Eur J Immunol (2010) 0.84
The natural killer cell response and tumor debulking are associated with prolonged survival in recurrent glioblastoma patients receiving dendritic cells loaded with autologous tumor lysates. Oncoimmunology (2013) 0.84
Tumor associated antigen and interleukin-12 mRNA transfected dendritic cells enhance effector function of natural killer cells and antigen specific T-cells. Clin Immunol (2008) 0.84
Dendritic cell cross talk with innate and innate-like effector cells in antitumor immunity: implications for DC vaccination. Crit Rev Immunol (2014) 0.83
Interleukin-15 dendritic cells as vaccine candidates for cancer immunotherapy. Hum Vaccin Immunother (2013) 0.82
Natural killer cells: the secret weapon in dendritic cell vaccination strategies. Clin Cancer Res (2014) 0.82
CD40-independent natural killer-cell help promotes dendritic cell vaccine-induced T-cell immunity against endogenous B-cell lymphoma. Int J Cancer (2014) 0.80
Quantification of IFN-gamma produced by human purified NK cells following tumor cell stimulation: comparison of three IFN-gamma assays. J Immunol Methods (2009) 0.79
Circulating HLA-DR(+) natural killer cells have potent lytic ability and weak antigen-presenting cell function. Hum Immunol (2008) 0.78
Dysfunction of dendritic cells in aged C57BL/6 mice leads to failure of natural killer cell activation and of tumor eradication. Proc Natl Acad Sci U S A (2014) 0.78
Acute myeloid leukemic cell lines loaded with synthetic dsRNA trigger IFN-gamma secretion by human NK cells. Leuk Res (2008) 0.78
HPV vaccine stimulates cytotoxic activity of killer dendritic cells and natural killer cells against HPV-positive tumour cells. J Cell Mol Med (2014) 0.77
STAT3 signaling contributes to the high effector activities of interleukin-15-derived dendritic cells. Immunol Cell Biol (2015) 0.77